A pilot randomised controlled trial of the Tailored Intervention for people with moderate-to-severe Chronic Obstructive Pulmonary Disease and Co-morbidities delivered by Pharmacists and Consultant respiratory Physicians (TICC-PCP)
To achieve progression criteria for a definitive phase three randomised controlled trial (RCT). Prospective phase two multicentre parallel-group RCT. Participants recruited from secondary care respiratory clinics in two health boards in Scotland, United Kingdom. 110 adults with moderate-severe COPD and co-morbidities. Tailored Intervention for COPD and Co-morbidities by Pharmacists and Consultant Physicians (TICC-PCP): home visits (for a year) by generalist prescribing pharmacists collaborating with consultant respiratory physicians. Pharmacists assessed, prescribed, de-prescribed, and referred participants to health and social care services as appropriate, in addition to Usual Care (UC). Recruit ≥100 participants; deliver TICC-PCP to ≥70% intervention-arm participants; collect ≥90% in-person data; retain ≥80% participants until 21-months. Secondary outcomes include clinical and health service utilisation. Recruitment, data collection, retention and participant retention targets were achieved over 21 months. TICC-PCP delivery: the median number of contacts, nine per participant in one year, matched the a-priori target although fewer than expected (13 (27%)) received the planned schedule of contacts (monthly for six months then every other month for six months). Secondary outcomes included increased prescribing of bone strengthening medicines, de-prescribing of medicines associated with increasing falls risk; delayed time to emergency health care contacts, fewer exacerbations; improved health related quality of life and longer duration of hospitalisation. A definitive phase three RCT of TICC-PCP may improve outcomes for people with moderate-severe COPD and co-morbidities. Trial registration: The trial is registered with the UK Clinical Trials Registry ( https://doi.org/10.1186/ISRCTN43508703 ). Registration date: 3/1/2020.
Authors
- Bethany Stanley (ORCID: https://orcid.org/0000-0003-3299-4014)
- Gillian Cameron (ORCID: https://orcid.org/0009-0002-4921-0482)
- Emma McIntosh (ORCID: https://orcid.org/0000-0001-6340-3083)
- Aziz Sheikh (ORCID: https://orcid.org/0000-0001-7022-3056)
- Andrew McPherson (ORCID: https://orcid.org/0000-0003-0420-8629)
- Nicola Greenlaw (ORCID: https://orcid.org/0000-0003-3847-1126)
- Karen Wood (ORCID: https://orcid.org/0000-0002-3671-0384)
- Frances S Mair (ORCID: https://orcid.org/0000-0001-9780-1135)
- Elaine Rankine
- Lynda Attwood
- Richard Lowrie (ORCID: https://orcid.org/0000-0002-6440-9089)
- Jane Moir
- Donald C. Noble
- Fiona Hughes
- Hannah Scobie (ORCID: https://orcid.org/0000-0001-9082-3913)
- Samuel Owusu Achiaw (ORCID: https://orcid.org/0009-0000-5711-7240)
- David Anderson (ORCID: https://orcid.org/0000-0002-2995-2553)
- Larry Tait
- Jennifer Anderson
Institutions
- NHS Lothian (GB)
- NHS Greater Glasgow and Clyde (GB)
- University of Oxford (GB)
- University of Glasgow (GB)
- University of Edinburgh (GB)
Publication Details
- Journal
- npj Primary Care Respiratory Medicine
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1038/s41533-025-00451-9
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chiesi Farmaceutici
- NHS Greater Glasgow and Clyde